UY36202A - Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer - Google Patents

Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer

Info

Publication number
UY36202A
UY36202A UY0001036202A UY36202A UY36202A UY 36202 A UY36202 A UY 36202A UY 0001036202 A UY0001036202 A UY 0001036202A UY 36202 A UY36202 A UY 36202A UY 36202 A UY36202 A UY 36202A
Authority
UY
Uruguay
Prior art keywords
recombinant hemoglobin
therapeutic agent
pharmaceutical composition
cancer treatment
subunities
Prior art date
Application number
UY0001036202A
Other languages
English (en)
Inventor
Wai Norman Fung Man
Kwok Sui Yi
Wong Bing Lou
Original Assignee
Wong Bing Lou
Wai Norman Fung Man
Kwok Sui Yi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wong Bing Lou, Wai Norman Fung Man, Kwok Sui Yi filed Critical Wong Bing Lou
Publication of UY36202A publication Critical patent/UY36202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición farmacéutica que contiene proteína o tetrámero o dímero o subunidad de hemoglobina recombinante para la oxigenación tisular y el tratamiento del cáncer. Un agente terapéutico basado en proteína o tetrámero o dímero o subunidad de hemoglobina recombinante. El resto de hemoglobina recombinante o tetrámero o dímero o su subunidad puede ser dirigido hacia células cancerígenas y el resto terapéutico (agente activo/ fármaco terapéutico) puede matar a las células cancerígenas en forma eficaz. La composición puede utilizarse por sí sola o en combinación con otro(s) agente(s) terapéutico(s) tales como un agente quimioterapéutico, un agente radioterapéutico, un fármaco proteico anticancerígeno.
UY0001036202A 2014-07-02 2015-07-02 Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer UY36202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462019925P 2014-07-02 2014-07-02
US14/752,999 US9814759B2 (en) 2014-07-02 2015-06-28 Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment

Publications (1)

Publication Number Publication Date
UY36202A true UY36202A (es) 2016-01-29

Family

ID=55016241

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036202A UY36202A (es) 2014-07-02 2015-07-02 Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer

Country Status (12)

Country Link
US (1) US9814759B2 (es)
EP (1) EP3164412A4 (es)
KR (1) KR20170026485A (es)
CN (1) CN106715468A (es)
AR (1) AR101101A1 (es)
AU (1) AU2015283394B2 (es)
CA (1) CA2953173A1 (es)
HK (1) HK1232242A1 (es)
SG (2) SG10201807554QA (es)
TW (1) TWI633118B (es)
UY (1) UY36202A (es)
WO (1) WO2016000616A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005013A (es) 2013-10-18 2017-02-28 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
WO2019003155A1 (en) * 2017-06-27 2019-01-03 Vision Global Holdings Limited COMPOSITIONS FOR PHOTODYNAMIC THERAPY AND FLUORESCENCE DIAGNOSIS OF CANCERS AND OTHER DISEASES
CN110256571A (zh) * 2018-11-30 2019-09-20 莱尔芙高新技术(上海)有限公司 重组人白蛋白-血红蛋白β亚基融合蛋白
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
US20220241765A1 (en) * 2019-05-24 2022-08-04 Glytech, Inc. Novel artificial protein catalyst
WO2021013131A1 (en) * 2019-07-19 2021-01-28 Cheer Global Limited Hemoglobin-based therapeutic agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US5449759A (en) 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US6172039B1 (en) * 1990-04-16 2001-01-09 Apex Bioscience, Inc. Expression of recombinant hemoglobin and hemoglobin variants in yeast
JP3426599B2 (ja) * 1991-11-08 2003-07-14 ヘモゾル インコーポレイテッド 薬物担体としてのヘモグロビン
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US7338670B2 (en) * 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8742073B2 (en) 2010-05-27 2014-06-03 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US20140106004A1 (en) 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
TWI610685B (zh) * 2013-05-13 2018-01-11 視界全球控股有限公司 用於癌症標靶治療及診斷成像之包含經修飾的基於血紅素之治療劑的醫藥組成物

Also Published As

Publication number Publication date
US9814759B2 (en) 2017-11-14
SG10201807554QA (en) 2018-10-30
HK1232242A1 (zh) 2018-01-05
WO2016000616A1 (en) 2016-01-07
EP3164412A4 (en) 2018-03-28
SG11201610947UA (en) 2017-01-27
US20160000864A1 (en) 2016-01-07
EP3164412A1 (en) 2017-05-10
AR101101A1 (es) 2016-11-23
AU2015283394A1 (en) 2017-01-19
TWI633118B (zh) 2018-08-21
TW201613960A (en) 2016-04-16
KR20170026485A (ko) 2017-03-08
CA2953173A1 (en) 2016-01-07
CN106715468A (zh) 2017-05-24
AU2015283394B2 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
DOP2017000156A (es) Derivados de glucagón con estabilidad mejorada
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
CL2015002736A1 (es) Composición farmacéutica de clorhidrato de s-ketamina.
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
CR20170361A (es) Forma de dosificación que incluye una solución sólida de drogas amorfas
UY36075A (es) Derivados de tubulisina
MX2024010140A (es) Nuevos metodos.
PE20170392A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CO2019014671A2 (es) Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CO2017003263A2 (es) Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
MX2015011775A (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxis.
CL2015001574A1 (es) Terapia combinada para el cancer
AR106351A1 (es) Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
BR112019022459A2 (pt) Agente terapêutico para câncer no sangue

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705